文献速递冠心病

冠脉支架术后长期氯吡格雷与阿司匹林单药治疗:按出血风险与PCI复杂度的分析

Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity.
PubMed 文献 · JAMA Cardiol · 2025-01-01

本分析基于韩国37中心HOST-EXAM Extended开放标签试验的事后数据,纳入PCI后DAPT无事件维持6-18个月的患者3974例,比较氯吡格雷与阿司匹林单药治疗。结果显示,无论是否存在高出血风险(HBR)和/或复杂PCI,氯吡格雷较阿司匹林均与更低的血栓和出血事件发生率相关。

要点

  • PCI后DAPT无事件6-18个月者,氯吡格雷单药优于阿司匹林单药
  • HBR患者血栓复合终点HR 0.75(95%CI 0.53-1.04),无HBR者HR 0.62(95%CI 0.48-0.80)
  • 复杂PCI者血栓复合终点HR 0.49(95%CI 0.32-0.77),非复杂PCI者HR 0.74(95%CI 0.59-0.92)

核心结论

  • 在PCI后DAPT 6-18个月无事件的患者中,氯吡格雷单药较阿司匹林单药的获益不受出血风险和/或PCI复杂度影响。

研究设计与样本

  • 纳入PCI后DAPT无事件维持6-18个月的患者,按1:1随机接受氯吡格雷或阿司匹林,分析其中可评估HBR或复杂PCI者共3974例(平均年龄63.4岁,男性2976例[74.9%])。

主要发现

  • 866例(21.8%)存在HBR,849例(21.4%)接受复杂PCI。
  • 血栓复合终点:HBR者HR 0.75(95%CI 0.53-1.04),无HBR者HR 0.62(95%CI 0.48-0.80),交互P=0.38;复杂PCI者HR 0.49(95%CI 0.32-0.77),非复杂PCI者HR 0.74(95%CI 0.59-0.92),交互P=0.12。
  • 任何出血:HBR者HR 0.82(95%CI 0.56-1.21),无HBR者HR 0.58(95%CI 0.40-0.85),交互P=0.20;复杂PCI者HR 0.79(95%CI 0.47-1.33),非复杂PCI者HR 0.68(95%CI 0.50-0.93),交互P=0.62。

关键数值与推荐

  • 血栓复合终点包括心血管死亡、非致死性心肌梗死、卒中、因急性冠脉综合征再入院及明确/可能的支架血栓。
  • 出血终点为Bleeding Academic Research Consortium 2-5型出血。

临床怎么用

  • 对PCI后DAPT 6-18个月无事件的患者,可考虑氯吡格雷单药替代阿司匹林,HBR或复杂PCI者同样可能获益。

局限性

  • 为事后分析,HBR与复杂PCI亚组样本量有限,部分HR的95%CI跨越1且交互P值均未达显著。
  • 开放标签设计,结论需在更大样本的前瞻性研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Antiplatelet monotherapy in the chronic maintenance period for patients with high bleeding risk (HBR) and those who have undergone complex percutaneous coronary intervention (PCI) has not yet been explored. OBJECTIVE: To compare clopidogrel vs aspirin monotherapy in patients with HBR and/or PCI complexity. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of the multicenter HOST-EXAM Extended study, an open-label trial conducted across 37 sites in South Korea, enrolled patients from 2014 to 2018 with up to 5.9 years of follow-up. The analysis was conducted from February to November 2023. Patients who maintained dual antiplatelet therapy (DAPT) event-free for 6 to 18 months following PCI were included. INTERVENTIONS: Patients were randomized to receive either clopidogrel or aspirin in a 1:1 ratio. Those with sufficient data to assess HBR or complex PCI were analyzed. MAIN OUTCOMES AND MEASURES: Coprimary end points were thrombotic composite end point (cardiovascular death, nonfatal myocardial infarction, stroke, readmission due to acute coronary syndrome, and definite/probable stent thrombosis) and any bleeding (Bleeding Academic Research Consortium type 2 to 5). RESULTS: Of 3974 patients included (mean [SD] age, 63.4 [10.7] years; 2976 male [74.9%]), 866 had HBR (21.8%), and 849 underwent complex PCI (21.4%). Clopidogrel as compared with aspirin was associated with lower rates of thrombotic and bleeding events regardless of HBR and/or PCI complexity. For the thrombotic composite end point, the hazard ratio (HR) was 0.75 (95% CI, 0.53-1.04) among HBR vs 0.62 (95% CI, 0.48-0.80) among patients without HBR (P for interaction = 0.38) and 0.49 (95% CI, 0.32-0.77) among patients with complex PCI vs 0.74 (95% CI, 0.59-0.92) among patients with noncomplex PCI (P for interaction = 0.12). The reduction in bleeding by clopidogrel compared with aspirin was consistent among both patients with HBR (HR, 0.82; 95% CI, 0.56-1.21) and patients without HBR (HR, 0.58; 95% CI, 0.40-0.85; P for interaction = 0.20) and among patients undergoing complex PCI (HR, 0.79; 95% CI, 0.47-1.33) vs noncomplex PCI (HR, 0.68; 95% CI, 0.50-0.93; P for interaction = 0.62). CONCLUSIONS AND RELEVANCE: In this study, in patients who experienced PCI and were event-free during 6 to 18 months of DAPT, the beneficial impact of clopidogrel monotherapy over aspirin monotherapy was consistent, regardless of bleeding risk and/or PCI complexity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02044250.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Kang, Chung, Park, et al. Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity. JAMA Cardiol. 2025. PMID: 39602157. doi:10.1001/jamacardio.2024.4030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。